Your payment is in progress...
  +1 (704) 266-3234

Global And China Neurological Disorder Drugs Market Insights, Forecast To 2026

Published on: Oct 2020 | From USD $3900 | Published By: QY RESEARCH | Number Of Pages: 128

Neurological Disorder Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Neurological Disorder Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Neurological Disorder Drugs market is segmented into
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others

Segment by Application, the Neurological Disorder Drugs market is segmented into
Hospital
Clinic

Regional and Country-level Analysis
The Neurological Disorder Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neurological Disorder Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Neurological Disorder Drugs Market Share Analysis
Neurological Disorder Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neurological Disorder Drugs business, the date to enter into the Neurological Disorder Drugs market, Neurological Disorder Drugs product introduction, recent developments, etc.
The major vendors covered:
Novartis AG
GlaxoSmithKline plc
Merck & Co.
Bayer AG
AstraZeneca
Boehringer Ingelheim GmbH
Teva Pharmaceutical
...

1 Study Coverage
1.1 Neurological Disorder Drugs Product Introduction
1.2 Market Segments
1.3 Key Neurological Disorder Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type
1.4.2 Antipsychotic
1.4.3 Hypnotic & Sedative
1.4.4 Analgesics
1.4.5 Anticoagulants
1.4.6 Others
1.5 Market by Application
1.5.1 Global Neurological Disorder Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Neurological Disorder Drugs Market Size, Estimates and Forecasts
2.1.1 Global Neurological Disorder Drugs Revenue 2015-2026
2.1.2 Global Neurological Disorder Drugs Sales 2015-2026
2.2 Global Neurological Disorder Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Neurological Disorder Drugs Historical Market Size by Region (2015-2020)
2.3.1 Global Neurological Disorder Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Neurological Disorder Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Neurological Disorder Drugs Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Neurological Disorder Drugs Sales Forecast by Region (2021-2026)
2.4.2 Global Neurological Disorder Drugs Revenue Forecast by Region (2021-2026)

3 Global Neurological Disorder Drugs Competitor Landscape by Players
3.1 Global Top Neurological Disorder Drugs Sales by Manufacturers
3.1.1 Global Neurological Disorder Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Neurological Disorder Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Global Neurological Disorder Drugs Manufacturers by Revenue
3.2.1 Global Neurological Disorder Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Neurological Disorder Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neurological Disorder Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neurological Disorder Drugs Revenue in 2019
3.2.5 Global Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Neurological Disorder Drugs Price by Manufacturers
3.4 Global Neurological Disorder Drugs Manufacturing Base Distribution, Product Types
3.4.1 Neurological Disorder Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neurological Disorder Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Neurological Disorder Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Neurological Disorder Drugs Market Size by Type (2015-2020)
4.1.1 Global Neurological Disorder Drugs Sales by Type (2015-2020)
4.1.2 Global Neurological Disorder Drugs Revenue by Type (2015-2020)
4.1.3 Neurological Disorder Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neurological Disorder Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Neurological Disorder Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Neurological Disorder Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Neurological Disorder Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neurological Disorder Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Neurological Disorder Drugs Market Size by Application (2015-2020)
5.1.1 Global Neurological Disorder Drugs Sales by Application (2015-2020)
5.1.2 Global Neurological Disorder Drugs Revenue by Application (2015-2020)
5.1.3 Neurological Disorder Drugs Price by Application (2015-2020)
5.2 Neurological Disorder Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Neurological Disorder Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Neurological Disorder Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Neurological Disorder Drugs Price Forecast by Application (2021-2026)

6 China by Players, Type and Application
6.1 China Neurological Disorder Drugs Market Size YoY Growth 2015-2026
6.1.1 China Neurological Disorder Drugs Sales YoY Growth 2015-2026
6.1.2 China Neurological Disorder Drugs Revenue YoY Growth 2015-2026
6.1.3 China Neurological Disorder Drugs Market Share in Global Market 2015-2026
6.2 China Neurological Disorder Drugs Market Size by Players (International and Local Players)
6.2.1 China Top Neurological Disorder Drugs Players by Sales (2015-2020)
6.2.2 China Top Neurological Disorder Drugs Players by Revenue (2015-2020)
6.3 China Neurological Disorder Drugs Historic Market Review by Type (2015-2020)
6.3.1 China Neurological Disorder Drugs Sales Market Share by Type (2015-2020)
6.3.2 China Neurological Disorder Drugs Revenue Market Share by Type (2015-2020)
6.3.3 China Neurological Disorder Drugs Price by Type (2015-2020)
6.4 China Neurological Disorder Drugs Market Estimates and Forecasts by Type (2021-2026)
6.4.1 China Neurological Disorder Drugs Sales Forecast by Type (2021-2026)
6.4.2 China Neurological Disorder Drugs Revenue Forecast by Type (2021-2026)
6.4.3 China Neurological Disorder Drugs Price Forecast by Type (2021-2026)
6.5 China Neurological Disorder Drugs Historic Market Review by Application (2015-2020)
6.5.1 China Neurological Disorder Drugs Sales Market Share by Application (2015-2020)
6.5.2 China Neurological Disorder Drugs Revenue Market Share by Application (2015-2020)
6.5.3 China Neurological Disorder Drugs Price by Application (2015-2020)
6.6 China Neurological Disorder Drugs Market Estimates and Forecasts by Application (2021-2026)
6.6.1 China Neurological Disorder Drugs Sales Forecast by Application (2021-2026)
6.6.2 China Neurological Disorder Drugs Revenue Forecast by Application (2021-2026)
6.6.3 China Neurological Disorder Drugs Price Forecast by Application (2021-2026)

7 North America
7.1 North America Neurological Disorder Drugs Market Size YoY Growth 2015-2026
7.2 North America Neurological Disorder Drugs Market Facts & Figures by Country
7.2.1 North America Neurological Disorder Drugs Sales by Country (2015-2020)
7.2.2 North America Neurological Disorder Drugs Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada

8 Europe
8.1 Europe Neurological Disorder Drugs Market Size YoY Growth 2015-2026
8.2 Europe Neurological Disorder Drugs Market Facts & Figures by Country
8.2.1 Europe Neurological Disorder Drugs Sales by Country
8.2.2 Europe Neurological Disorder Drugs Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia

9 Asia Pacific
9.1 Asia Pacific Neurological Disorder Drugs Market Size YoY Growth 2015-2026
9.2 Asia Pacific Neurological Disorder Drugs Market Facts & Figures by Country
9.2.1 Asia Pacific Neurological Disorder Drugs Sales by Region (2015-2020)
9.2.2 Asia Pacific Neurological Disorder Drugs Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam

10 Latin America
10.1 Latin America Neurological Disorder Drugs Market Size YoY Growth 2015-2026
10.2 Latin America Neurological Disorder Drugs Market Facts & Figures by Country
10.2.1 Latin America Neurological Disorder Drugs Sales by Country
10.2.2 Latin America Neurological Disorder Drugs Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina

11 Middle East and Africa
11.1 Middle East and Africa Neurological Disorder Drugs Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Neurological Disorder Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Neurological Disorder Drugs Sales by Country
11.2.2 Middle East and Africa Neurological Disorder Drugs Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E

12 Company Profiles
12.1 Novartis AG
12.1.1 Novartis AG Corporation Information
12.1.2 Novartis AG Description and Business Overview
12.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Novartis AG Neurological Disorder Drugs Products Offered
12.1.5 Novartis AG Recent Development
12.2 GlaxoSmithKline plc
12.2.1 GlaxoSmithKline plc Corporation Information
12.2.2 GlaxoSmithKline plc Description and Business Overview
12.2.3 GlaxoSmithKline plc Sales, Revenue and Gross Margin (2015-2020)
12.2.4 GlaxoSmithKline plc Neurological Disorder Drugs Products Offered
12.2.5 GlaxoSmithKline plc Recent Development
12.3 Merck & Co.
12.3.1 Merck & Co. Corporation Information
12.3.2 Merck & Co. Description and Business Overview
12.3.3 Merck & Co. Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Merck & Co. Neurological Disorder Drugs Products Offered
12.3.5 Merck & Co. Recent Development
12.4 Bayer AG
12.4.1 Bayer AG Corporation Information
12.4.2 Bayer AG Description and Business Overview
12.4.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Bayer AG Neurological Disorder Drugs Products Offered
12.4.5 Bayer AG Recent Development
12.5 AstraZeneca
12.5.1 AstraZeneca Corporation Information
12.5.2 AstraZeneca Description and Business Overview
12.5.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
12.5.4 AstraZeneca Neurological Disorder Drugs Products Offered
12.5.5 AstraZeneca Recent Development
12.6 Boehringer Ingelheim GmbH
12.6.1 Boehringer Ingelheim GmbH Corporation Information
12.6.2 Boehringer Ingelheim GmbH Description and Business Overview
12.6.3 Boehringer Ingelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Boehringer Ingelheim GmbH Neurological Disorder Drugs Products Offered
12.6.5 Boehringer Ingelheim GmbH Recent Development
12.7 Teva Pharmaceutical
12.7.1 Teva Pharmaceutical Corporation Information
12.7.2 Teva Pharmaceutical Description and Business Overview
12.7.3 Teva Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Teva Pharmaceutical Neurological Disorder Drugs Products Offered
12.7.5 Teva Pharmaceutical Recent Development
12.11 Novartis AG
12.11.1 Novartis AG Corporation Information
12.11.2 Novartis AG Description and Business Overview
12.11.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Novartis AG Neurological Disorder Drugs Products Offered
12.11.5 Novartis AG Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Neurological Disorder Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neurological Disorder Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Neurological Disorder Drugs Market Segments
Table 2. Ranking of Global Top Neurological Disorder Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Neurological Disorder Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Antipsychotic
Table 5. Major Manufacturers of Hypnotic & Sedative
Table 6. Major Manufacturers of Analgesics
Table 7. Major Manufacturers of Anticoagulants
Table 8. Major Manufacturers of Others
Table 9. Global Neurological Disorder Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 10. Global Neurological Disorder Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 11. Global Neurological Disorder Drugs Sales by Regions 2015-2020 (K Units)
Table 12. Global Neurological Disorder Drugs Sales Market Share by Regions (2015-2020)
Table 13. Global Neurological Disorder Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Neurological Disorder Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 15. Global Neurological Disorder Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 16. Global Neurological Disorder Drugs Sales Share by Manufacturers (2015-2020)
Table 17. Global Neurological Disorder Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Neurological Disorder Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurological Disorder Drugs as of 2019)
Table 19. Neurological Disorder Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Neurological Disorder Drugs Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Neurological Disorder Drugs Price (2015-2020) (USD/Unit)
Table 22. Neurological Disorder Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Neurological Disorder Drugs Product Type
Table 24. Date of International Manufacturers Enter into Neurological Disorder Drugs Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)
Table 27. Global Neurological Disorder Drugs Sales Share by Type (2015-2020)
Table 28. Global Neurological Disorder Drugs Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Neurological Disorder Drugs Revenue Share by Type (2015-2020)
Table 30. Neurological Disorder Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 31. Global Neurological Disorder Drugs Sales Share by Type (2021-2026)
Table 32. Global Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)
Table 33. Global Neurological Disorder Drugs Sales Share by Application (2015-2020)
Table 34. Global Neurological Disorder Drugs Sales Share by Application (2021-2026)
Table 35. Global Neurological Disorder Drugs Sales Market Share Forecast by Application (2021-2026)
Table 36. Global Neurological Disorder Drugs Revenue by Application (2015-2020) (US$ Million)
Table 37. Global Neurological Disorder Drugs Revenue Market Share Forecast by Application (2021-2026)
Table 38. China Neurological Disorder Drugs Sales (K Units) of Key Companies (2015-2020)
Table 39. China Neurological Disorder Drugs Sales Share by Company (2015-2020)
Table 40. China Neurological Disorder Drugs Revenue (US$ Million) by Company (2015-2020)
Table 41. China Neurological Disorder Drugs Sales (K Units) by Type (2015-2020)
Table 42. China Neurological Disorder Drugs Sales Share by Type (2015-2020)
Table 43. China Neurological Disorder Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 44. China Neurological Disorder Drugs Price (K Units) by Type (2015-2020)
Table 45. China Neurological Disorder Drugs Sales (K Units) by Type (2021-2026)
Table 46. China Neurological Disorder Drugs Sales Share by Type (2021-2026)
Table 47. China Neurological Disorder Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 48. China Neurological Disorder Drugs Revenue Share by Type (2021-2026)
Table 49. China Neurological Disorder Drugs Price (K Units) by Type (2021-2026)
Table 50. China Neurological Disorder Drugs Sales (K Units) by Application (2015-2020)
Table 51. China Neurological Disorder Drugs Sales Share by Application (2015-2020)
Table 52. China Neurological Disorder Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 53. China Neurological Disorder Drugs Sales (K Units) by Application (2021-2026)
Table 54. China Neurological Disorder Drugs Sales Share by Application (2021-2026)
Table 55. China Neurological Disorder Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 56. China Neurological Disorder Drugs Revenue Share by Application (2021-2026)
Table 57. North America Neurological Disorder Drugs Sales by Country (2015-2020) (K Units)
Table 58. North America Neurological Disorder Drugs Sales Market Share by Country (2015-2020)
Table 59. North America Neurological Disorder Drugs Revenue by Country (2015-2020) (US$ Million)
Table 60. North America Neurological Disorder Drugs Revenue Market Share by Country (2015-2020)
Table 61. Europe Neurological Disorder Drugs Sales by Country (2015-2020) (K Units)
Table 62. Europe Neurological Disorder Drugs Sales Market Share by Country (2015-2020)
Table 63. Europe Neurological Disorder Drugs Revenue by Country (2015-2020) (US$ Million)
Table 64. Europe Neurological Disorder Drugs Revenue Market Share by Country (2015-2020)
Table 65. Asia Pacific Neurological Disorder Drugs Sales by Region (2015-2020) (K Units)
Table 66. Asia Pacific Neurological Disorder Drugs Sales Market Share by Region (2015-2020)
Table 67. Asia Pacific Neurological Disorder Drugs Revenue by Region (2015-2020) (US$ Million)
Table 68. Asia Pacific Neurological Disorder Drugs Revenue Market Share by Region (2015-2020)
Table 69. Latin America Neurological Disorder Drugs Sales by Country (2015-2020) (K Units)
Table 70. Latin America Neurological Disorder Drugs Sales Market Share by Country (2015-2020)
Table 71. Latin Americaa Neurological Disorder Drugs Revenue by Country (2015-2020) (US$ Million)
Table 72. Latin America Neurological Disorder Drugs Revenue Market Share by Country (2015-2020)
Table 73. Middle East and Africa Neurological Disorder Drugs Sales by Country (2015-2020) (K Units)
Table 74. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Country (2015-2020)
Table 75. Middle East and Africa Neurological Disorder Drugs Revenue by Country (2015-2020) (US$ Million)
Table 76. Middle East and Africa Neurological Disorder Drugs Revenue Market Share by Country (2015-2020)
Table 77. Novartis AG Corporation Information
Table 78. Novartis AG Description and Business Overview
Table 79. Novartis AG Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Novartis AG Neurological Disorder Drugs Product
Table 81. Novartis AG Recent Development
Table 82. GlaxoSmithKline plc Corporation Information
Table 83. GlaxoSmithKline plc Description and Business Overview
Table 84. GlaxoSmithKline plc Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. GlaxoSmithKline plc Product
Table 86. GlaxoSmithKline plc Recent Development
Table 87. Merck & Co. Corporation Information
Table 88. Merck & Co. Description and Business Overview
Table 89. Merck & Co. Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Merck & Co. Product
Table 91. Merck & Co. Recent Development
Table 92. Bayer AG Corporation Information
Table 93. Bayer AG Description and Business Overview
Table 94. Bayer AG Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Bayer AG Product
Table 96. Bayer AG Recent Development
Table 97. AstraZeneca Corporation Information
Table 98. AstraZeneca Description and Business Overview
Table 99. AstraZeneca Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. AstraZeneca Product
Table 101. AstraZeneca Recent Development
Table 102. Boehringer Ingelheim GmbH Corporation Information
Table 103. Boehringer Ingelheim GmbH Description and Business Overview
Table 104. Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. Boehringer Ingelheim GmbH Product
Table 106. Boehringer Ingelheim GmbH Recent Development
Table 107. Teva Pharmaceutical Corporation Information
Table 108. Teva Pharmaceutical Description and Business Overview
Table 109. Teva Pharmaceutical Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 110. Teva Pharmaceutical Product
Table 111. Teva Pharmaceutical Recent Development
Table 112. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 113. Key Challenges
Table 114. Market Risks
Table 115. Main Points Interviewed from Key Neurological Disorder Drugs Players
Table 116. Neurological Disorder Drugs Customers List
Table 117. Neurological Disorder Drugs Distributors List
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Neurological Disorder Drugs Product Picture
Figure 2. Global Neurological Disorder Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Antipsychotic Product Picture
Figure 4. Hypnotic & Sedative Product Picture
Figure 5. Analgesics Product Picture
Figure 6. Anticoagulants Product Picture
Figure 7. Others Product Picture
Figure 8. Global Neurological Disorder Drugs Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Neurological Disorder Drugs Report Years Considered
Figure 12. Global Neurological Disorder Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Neurological Disorder Drugs Sales 2015-2026 (K Units)
Figure 14. Global Neurological Disorder Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Neurological Disorder Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Neurological Disorder Drugs Sales Market Share by Region in 2019
Figure 17. Global Neurological Disorder Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Neurological Disorder Drugs Revenue Market Share by Region in 2019
Figure 19. Global Neurological Disorder Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Neurological Disorder Drugs Revenue in 2019
Figure 21. Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Neurological Disorder Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Neurological Disorder Drugs Sales Market Share by Type in 2019
Figure 24. Global Neurological Disorder Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Neurological Disorder Drugs Revenue Market Share by Type in 2019
Figure 26. Global Neurological Disorder Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Neurological Disorder Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Neurological Disorder Drugs Sales Market Share by Application in 2019
Figure 29. Global Neurological Disorder Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Neurological Disorder Drugs Revenue Market Share by Application in 2019
Figure 31. China Neurological Disorder Drugs Sales Growth Rate 2015-2026 (K Units)
Figure 32. China Neurological Disorder Drugs Revenue Growth Rate 2015-2026 (US$ Million)
Figure 33. China Neurological Disorder Drugs Market Share in Global Market 2015-2026
Figure 34. China 5 and 10 Largest Neurological Disorder Drugs Players Market Share by Revenue in Neurological Disorder Drugs in 2019
Figure 35. China Neurological Disorder Drugs Revenue Share by Type (2015-2020)
Figure 36. China Neurological Disorder Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 37. China Neurological Disorder Drugs Revenue Share by Application (2015-2020)
Figure 38. China Neurological Disorder Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 39. North America Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 40. North America Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 41. North America Neurological Disorder Drugs Sales Market Share by Country in 2019
Figure 42. North America Neurological Disorder Drugs Revenue Market Share by Country in 2019
Figure 43. U.S. Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 44. U.S. Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. Canada Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 46. Canada Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. Europe Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 48. Europe Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 49. Europe Neurological Disorder Drugs Sales Market Share by Country in 2019
Figure 50. Europe Neurological Disorder Drugs Revenue Market Share by Country in 2019
Figure 51. Germany Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 52. Germany Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. France Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 54. France Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. U.K. Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 56. U.K. Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Italy Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 58. Italy Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Russia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 60. Russia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Asia Pacific Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 62. Asia Pacific Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 63. Asia Pacific Neurological Disorder Drugs Sales Market Share by Region in 2019
Figure 64. Asia Pacific Neurological Disorder Drugs Revenue Market Share by Region in 2019
Figure 65. China Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 66. China Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Japan Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 68. Japan Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. South Korea Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 70. South Korea Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. India Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 72. India Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Australia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 74. Australia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Taiwan Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 76. Taiwan Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Indonesia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 78. Indonesia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Thailand Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 80. Thailand Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Malaysia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 82. Malaysia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Philippines Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 84. Philippines Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Vietnam Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 86. Vietnam Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Latin America Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 88. Latin America Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Neurological Disorder Drugs Sales Market Share by Country in 2019
Figure 90. Latin America Neurological Disorder Drugs Revenue Market Share by Country in 2019
Figure 91. Mexico Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 92. Mexico Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 94. Brazil Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 96. Argentina Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Middle East and Africa Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 98. Middle East and Africa Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Neurological Disorder Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 102. Turkey Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 104. Saudi Arabia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 106. U.A.E Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Porter's Five Forces Analysis
Figure 108. Neurological Disorder Drugs Value Chain
Figure 109. Channels of Distribution
Figure 110. Distributors Profiles
Figure 111. Bottom-up and Top-down Approaches for This Report
Figure 112. Data Triangulation
Figure 113. Key Executives Interviewed

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $3900
USD $5850
USD $7800
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.